& & 1- By intraarticular or soft tissue injection: in cases of: osteoarthritis, rheumatoid arthritis, bursitis, gouty arthritis, epicondylitis,
& & tenosynovitis, myositis, fibrositis.
& & 2- By intralesional injection: in cases of: keloids, alopecia aerate, lichen simplex, granuloma annulare, and discoid lupus.
& & 3- As systemic therapy:
& & – In rheumatic and collagen disease e.g. rheumatoid arhritis, systemic lupus erythematosis, ankylosing spondylitis and other
& & spongyloarthropathies, osteoarthritis, and psoriatic arthritis.
& & – In allergic states e.g. bronchial asthma, atopic dermatitis, serum sickness, angioneurotic edema.
& & – In dermatologic diseases e.g. pemphigus, severe erythema multiforme (Stevens Johnson syndrome) and severe psoriasis
& & or seborrheic dermatitis.
& & – In other medical diseases e.g. shock, nephrotic syndrome, ulcerative bowel disease, idiopathic thrombocytopenic purpura,
& & acquired autoimmune hemolytic anemia, adrenocortical insufficiency and hirsutism due to adrenal hypercorticism.
& & – For diagnostic testing of adrenocortical hyperfunction (Dexamethasone suppression test).
* Dosage: Dosage requirements of Dexamethasone are variable and must be individualized on the basis of the disease &&
& & the response of the patient.
& & – Local therapy (intraarticular, intralesional or soft tissue injection): the usual dose is 0.2-6 mg.
& & The frequency ranges from twice weekly to once every 2-3 weeks.
& & – Systemic therapy (IM or IV): an initial daily dosage of 0.5-8 mg can be given. After obtaining a satisfactory clinical response,
& & the dose can be reduced to the lowest effective maintenance dose. Maximum acceptable dose for long term use is 1.5 mg / day.